



## ASX ANNOUNCEMENT

15 January 2015

### TOP 20 SHAREHOLDERS

Rank	Holder Name	Shares	%
1	CELTIC CAPITAL PTE LTD <TRADING 1 A/C>	2,650,000	4.01%
2	PROFESSOR IGOR SLUKVIN	2,383,317	3.61%
3	MR IAN DIXON	2,383,317	3.61%
4	EQUITAS NOMINEES PTY LTD <GROUP A A/C>	1,937,300	2.93%
5	TISIA NOMINEES PTY LTD <HENDERSON FAMILY A/C>	1,920,059	2.91%
6	DR ALLEN BOLLANDS	1,787,488	2.71%
7	DR ROGER ASTON	1,787,488	2.71%
8	JOHN W KING NOMINEES PTY LTD	1,780,000	2.69%
9	JK NOMINEES PTY LTD<THE JK FUND A/C>	1,750,000	2.65%
10	DENLIN NOMINEES PTY LTD	1,646,916	2.49%
11	ARDROY SECURITIES PTY LTD <CAMERON INVESTMENT UNIT A/C>	1,470,211	2.23%
12	WEBINVEST PTY LTD <OSLB UNIT A/C>	1,325,000	2.01%
13	BANNABY INVESTMENTS PTY LTD <BANNABY SUPER FUND A/C>	1,293,916	1.96%
14	DR MAKYSM VODYANYK	1,191,658	1.80%
15	INTERSUISSE NOMINEES PTY LTD <CUSTODIAN A/C>	1,181,257	1.79%
16	MR GREGORY PINKUS & MRS LISA PINKUS <PINKUS FAMILY SUPER FUND A/C>	850,000	1.29%
17	MR GRANT PATERSON <GTP FAMILY A/C>	793,916	1.20%
18	MR PETER CAPP <CAPP FAMILY A/C>	700,000	1.06%
19	CM COOK SUPERANNUATION PTY LTD	700,000	1.06%
20	AVIEMORE CAPITAL PTY LTD	689,046	1.04%
		<b>30,220,889</b>	<b>45.76%</b>

**Media contacts:** Dr Ross Macdonald, CEO: Tel: 0412 119343; email [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
 Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email [stewart.washer@cynata.com](mailto:stewart.washer@cynata.com)

### About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.